The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

Table 2 Correlation between clinical outcomes and change in biomarkers at week 12 for patients in all treatment groups

	C1M	C2M	C3M	C4M	CTX-I	CRP
Hybrid ACR	− 0.33***	− 0.06	− 0.31***	− 0.38***	− 0.13	− 0.44***
CDAI	0.1	0.05	0.19**	0.18**	0.16*	0.18**
SDAI	0.18**	0.04	0.23***	0.24***	0.15*	0.25***
HAQ-DI	0.24 ***	− 0.02	0.21**	0.33***	0.09	0.28***
DAS28-ESR	0.35***	0	0.34***	0.35***	0.14*	0.43***
SJC66	− 0.05	0.02	0.15*	0.11	0.1	0.01
TJC68	0.06	0.09	0.13*	0.1	0.1	0.08

Numbers represent Spearman’s rank correlation coefficient value
ACR American College of Rheumatology; C1M metalloproteinase-derived fragments of type I, of type II (C2M), type III (C3M), and type IV (C4M) collagen; CDAI Clinical Disease Activity Index; CRP C-reactive protein; CTX-I C-terminal telopeptide of type I collagen; DAS28 Disease Activity Score 28 joints; ESR erythrocyte sedimentation rate; HAQ-DI Health Assessment Questionnaire-Disability Index; SDAI Simplified Disease Activity Index; SJC66 swollen joint count of 66 joints; TJC68 tender joint count of 68 joints
*p value ≤ 0.05; **p value ≤ 0.01; ***p value ≤ 0.001

ISSN: 1478-6362